A5019710866- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Anesthesia and Pain Management
- Advanced Breast Cancer Therapies
- Liver Disease Diagnosis and Treatment
- Sirtuins and Resveratrol in Medicine
- Inflammatory mediators and NSAID effects
- Medicinal Plants and Neuroprotection
- Cancer Diagnosis and Treatment
- Pneumonia and Respiratory Infections
- Viral-associated cancers and disorders
- Oral microbiology and periodontitis research
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Plant Disease Resistance and Genetics
- Histone Deacetylase Inhibitors Research
- Immune Response and Inflammation
- Biochemical and Molecular Research
Chinese Academy of Medical Sciences & Peking Union Medical College
2021-2025
National Clinical Research
2024
National Cancer Center
2024
Nanchang University
2019
Queen Mary University of London
2019
Sichuan University
2013
128 Background: Fruquintinib is a standard third-line treatment in metastatic colorectal cancer (mCRC). However, no therapeutic regimen available for mCRC patients who progressed on therapy. Preclinical experiments supported rationale combining antiangiogenic therapy and 5-fluorouracil (5FU) refractory with evidence synergy. This open-label phase Ib/II study was designed to determine the safety efficacy of fruquintinib plus 5-fluorouracil/leucovorin monotherapy. Methods: The enrolled would...
342 Background: With the publication of several clinical research results, efficacy ICI combined with chemotherapy has gradually been recognized in HER-2 negative advanced GC field. We analyzed 1st-line PD-1 inhibitor patients using real-world data and conducted exploratory analysis. aim to identify factors that can predict treatment efficacy, provide a basis for practice. Methods: prospectively collected from between November 2020 April 2024. The staging was stage IV. All were HER2 pMMR....
155 Background: Metastatic colorectal cancer (mCRC) patients have poor prognoses with limited response to second-line chemotherapy. Therefore, it is urgent refine and design an optimal treatment regimen improve the rate prolong survival of mCRC. This study assessed safety efficacy trifluridine/tipiracil (TAS-102), irinotecan, bevacizumab in settings for mCRC patients. Methods: was a multicenter, single-arm, phase II trial. The who are refractory standard first-line treatment, including...
The 5-fuorouracil, oxaliplatin and irinotecan (FOLFOXIRI) regimen is the standard first-line treatment for advanced pancreatic cancer (APC). Capecitabine, an oral prodrug of 5-fluorouracil, offers a more convenient potentially safer alternative. We evaluated efficacy safety XELOXIRI (capecitabine, oxaliplatin, irinotecan) in Chinese patients with APC. This real-world study consecutive treated as chemotherapy APC at national center China from August 2019 to June 2024. Treatment was assessed...
BACKGROUND Glycolysis provides growth advantages and leads to drug resistance in colorectal cancer (CRC) cells. SIRT1, an NAD+-dependent deacetylase, regulates various cellular processes, its upregulation results antitumor effects. This study investigated the role of SIRT1 metabolic reprogramming oxaliplatin CRC AIM To investigate overcoming METHODS We performed transcriptome sequencing human parental cells oxaliplatin-resistant identify differentially expressed genes. Key regulators were...
This case report details a patient with Pancreatic Acinar Cell Carcinoma (PACC), rare malignancy distinctive biological and imaging features. In the absence of standardized treatment protocols for PACC, we embarked on diagnostic journey that led to adoption an innovative therapeutic regimen in our institution. A 45-year-old female presented pancreatic mass, which was histologically confirmed as PACC following biopsy. Subsequent genomic profiling revealed high tumor mutational burden...
Purpose To explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM). Patients methods This was a dual-center, phase II trial rate no evidence disease (NED) achieved primary endpoint. All enrolled initially left-sided received modified therapy. Results Between October 2019 2021, fifteen were enrolled. Nine (60%) NED. The overall response (ORR) 92.9%, control (DCR) 100%....
BACKGROUND Although treatment options for gastric cancer (GC) continue to advance, the overall prognosis patients with GC remains poor. At present, predictors of efficacy remain controversial except high microsatellite instability. AIM To develop methods identify groups who would benefit most from receiving combination a programmed cell death protein 1 (PD-1) inhibitor and chemotherapy. METHODS We acquired data 63 human epidermal growth factor receptor 2 (HER2)-negative histological...
To explore the efficacy and safety of combination irinotecan, trifluridine/tipiracil (TAS-102), bevacizumab in a later-line setting for metastatic colorectal cancer (mCRC) patients.
Gallbladder mucinous adenocarcinoma (GBMAC) is a rare subtype of gallbladder (GBAC), with limited knowledge its survival outcomes from small case series and single-center retrospective analysis.To compare the clinicopathological characteristics GBMAC typical GBAC prognostic factors to gain insights into this field.This study was conducted using data Surveillance, Epidemiology, End Results database, including cases diagnosed 2010 2017. The Pearson chi-square test or Fisher exact used examine...
Pancreatic cancer (PC) is a leading cause of cancer-related death, given its poor prognosis and the limited benefits traditional therapies. As tumors become more genetically disorganized as they progress, genetic mutations might new markers for us to predict their behavior. Nowadays, many inhibitors can selectively target gene products form targeted therapy, with some showing promise treatment various types cancer.We describe rare case PC patient long-term survival than 8 yr. The was...